Drug Profile
LYN 00101
Alternative Names: Anti-VEGF monoclonal antibody - Lynkcell; LY00101; LYN00101Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Lynkcell
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cervical cancer; Colorectal cancer; Gastric cancer; Ovarian cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Cervical-cancer(Late-stage disease) in United Arab Emirates (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease) in United Arab Emirates (IV, Infusion)
- 28 May 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease) in United Arab Emirates (IV, Infusion)